FDA Regulation of Stem Cell-Based Products

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 1401 Rockville Pike, Suite 200N, Mail Code HFM-720, Rockville, MD 20852-1448, USA.
Science (Impact Factor: 31.48). 07/2009; 324(5935):1662-3. DOI: 10.1126/science.1173712
Source: PubMed

ABSTRACT Cell self-renewal and the capacity to differentiate into multiple cell types (pluripotency) are biological attributes casting stem cells as attractive candidates for development of therapies targeting indications that involve functional restoration of damaged tissues. In the United States, clinical trials designed to demonstrate the safety and effectiveness of stem cell-based products are regulated by the U.S. Food and Drug Administration (FDA). To ensure that subjects enrolled in a clinical study involving stem cell-based products are not exposed to significant and unreasonable risk, the FDA reviews medical and scientific information that encompasses delineation of product-specific characteristics and preclinical testing to determine whether there is sufficient safety assurance to permit initiation of human clinical studies.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Looking through the lens of the media reveals much about how new biotechnologies are portrayed and how these reports influence public policy and opinion. The roles of patients, scientists, and the government loom large in this equation. These stakeholders tell us what is important to them and why. But little research exists comparing representations of new clinical technologies in the mainstream media across time. What has changed in newspaper accounts of new biotechnologies since the 1970s? How are the stakeholders portrayed, and what do these individuals have to say? Here, we seek to answer these questions by examining media reporting of Laetrile and stem cell transplants during the time of their clinical advent.
    02/2014; 5(1). DOI:10.1080/21507716.2013.785988
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite advances in coronary artery disease treatment and prevention, myocardial damage due to acute myocardial infarction (MI) remains a major cause of morbidity and mortality in the population. Cell-based clinical trials to treat MI have focused on cells derived from the bone marrow or those potentially possessing functional similarities such as skeletal myoblasts or cardiac progenitors isolated from heart biopsies. Any benefits provided by these cells in improving heart function, left ventricular ejection fraction, or extending life expectancy after MI have been credited mostly to paracrine effects. Functional restoration of damaged myocardium will require a functional cell type with similar phenotype and characteristics of the damaged tissue that can also integrate, survive, and electrically couple to the host. Human pluripotent stem cells (hPSCs) have the ability to differentiate into multiple cell types of the adult body. hPSC-derived cardiomyocytes represent a promising target population for cell-based therapies for MI because they are scalable and the product can be defined with a specific set of release criteria. The purpose of this article is to review the rationale for cell therapy in heart disease, discuss the properties of hPSC cardiomyocytes that define their usefulness for regenerative therapy, consider manufacturing issues and preclinical investigation, and finally examine the steps required to establish effective clinical implementation. Pluripotent stem cell-derived cardiomyocyte-based therapies have enormous potential to revolutionize the management of heart disease; expedient but careful development is needed to ensure that this potential is fully realized. Copyright © 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
    The Canadian journal of cardiology 11/2014; 30(11):1335-1349. DOI:10.1016/j.cjca.2014.08.005 · 3.94 Impact Factor
  • The Global Dynamics of Regenerative Medicine. A Social Science Critique, Edited by Andrew Webster, 01/2013: pages 88-117; Palgrave Macmillan.

Full-text (2 Sources)

Available from
May 22, 2014